McNamara D, Di Salvo T, Mathier M, Keck S, Semigran M, Dec G W
Massachusetts General Hospital Heart Failure and Cardiac Transplantation Center, Boston, USA.
J Heart Lung Transplant. 1996 May;15(5):506-15.
The purpose of this study was to examine the incidence, natural history, and outcome of left ventricular dysfunction in 102 consecutive heart transplant recipients. Left ventricular dysfunction (defined as a decline in the echocardiographic ejection fraction to < 0.45) occurred in 16 of 102 transplant recipients (16%) at a mean of 9.7 +/- 8.6 (standard deviation) months after transplantation.
Diagnostic evaluation included right heart catheterization and endomyocardial biopsy in all patients and coronary angiography in 13 patients.
Four patients were found to have moderate cellular rejection (International Society for Heart and Lung Transplantation grade 2 or higher) and were treated with enhanced immunosuppression. Two patients had angiographically apparent coronary allograft vasculopathy; both died of electromechanical dissociation within 4 months. The remaining ten patients had no or mild cellular rejection (International Society for Heart and Lung Transplantation grade 0 or 1). Therapy in these ten patients included corticosteroids (n = 8). OKT3 (n = 5), and plasmapheresis (n = 2). Three patients died within 2 months of diagnosis, two from undetected severe coronary allograft vasculopathy and one from unrecognized constrictive pericarditis. The echocardiographic ejection fraction improved in the surviving patients after enhanced immunosuppressive therapy (0.33 to 0.53, p < 0.005). With the benefit of long-term clinical follow-up and autopsy data, the origins of left ventricular dysfunction in the 16 patients included moderate cellular rejection (n = 4), vascular rejection (n = 1), coronary allograft vasculopathy (n = 3), intercurrent cytomegalovirus infection (n = 1), constrictive pericarditis (n = 1), and either mild or no evident rejection (n = 6). Survival of the 16 patients with left ventricular dysfunction was similar to that of the 86 patients without left ventricular dysfunction.
The cause of left ventricular dysfunction after heart transplantation includes cellular rejection, vascular rejection, coronary allograft vasculopathy, cytomegalovirus infection, constrictive pericarditis, and unexplained mechanisms. Given the improvement in left ventricular function observed after empiric therapy with enhanced immunosuppression in patients with left ventricular dysfunction, immune-mediated phenomena may play an important pathogenic role.
本研究旨在调查102例连续心脏移植受者左心室功能障碍的发生率、自然病史及转归。102例移植受者中有16例(16%)发生左心室功能障碍(定义为超声心动图射血分数降至<0.45),平均发生于移植后9.7±8.6(标准差)个月。
所有患者均接受诊断性评估,包括右心导管检查和心内膜心肌活检,13例患者接受冠状动脉造影。
4例患者存在中度细胞排斥反应(国际心肺移植学会分级为2级或更高),接受强化免疫抑制治疗。2例患者有冠状动脉移植血管病变的血管造影表现;均在4个月内死于电机械分离。其余10例患者无或有轻度细胞排斥反应(国际心肺移植学会分级为0级或1级)。这10例患者的治疗包括使用皮质类固醇(n = 8)、OKT3(n = 5)和血浆置换(n = 2)。3例患者在诊断后2个月内死亡,2例死于未检测到的严重冠状动脉移植血管病变,1例死于未识别的缩窄性心包炎。强化免疫抑制治疗后,存活患者的超声心动图射血分数有所改善(从0.33提高至0.53,p<0.005)。受益于长期临床随访和尸检数据,16例患者左心室功能障碍的病因包括中度细胞排斥反应(n = 4)、血管排斥反应(n = 1)、冠状动脉移植血管病变(n = 3)、并发巨细胞病毒感染(n = 1)、缩窄性心包炎(n = 1)以及轻度或无明显排斥反应(n = 6)。16例左心室功能障碍患者的生存率与86例无左心室功能障碍患者的生存率相似。
心脏移植后左心室功能障碍的病因包括细胞排斥反应、血管排斥反应、冠状动脉移植血管病变、巨细胞病毒感染、缩窄性心包炎以及不明原因机制。鉴于左心室功能障碍患者经强化免疫抑制经验性治疗后左心室功能有所改善,免疫介导现象可能起重要致病作用。